DEA News
Return to News Home

OVID-19 Antivirals Can Trigger Viral Rebound, Study Finds

COVID-19 antivirals can trigger viral rebound in ambulatory patients, according to an analysis published on November 14, 2023 in Annals of Internal Medicine.

Marcus A Bank, Medscape, Nov 13, 2023




"For patients with COVID-19 with a low-risk for severe disease, the possibility of prolonged shedding should be factored into the consideration of potential risks and benefits of treatment," the researchers write.


Mark Siedner, MD, MPH, an infectious disease researcher at Massachusetts General Hospital in Boston is the study's corresponding author. The primary funder is the National Institutes of Health.


The study is observational and retrospective and relied on viral shedding as a proxy for contagiousness rather than directly measuring disease transmission.


Additional funders included the Massachusetts Consortium on Pathogen Readiness SARS CoV-2 Variants Program, and the Massachusetts General Hospital Department of Medicine. Various authors reported speaking or consulting relationships with pharmaceutical companies.

Return to News Home